Search research articles
Contact Us
Filters
Showing results (121-130 of 187) with videos related to
Page
of 19
Sort By:
Blood
|
April 1, 2011
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
Gabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, et al.
American Journal of Hematology
|
January 11, 2016
Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients
Alessandro Andriani, Roberto Latagliata, Barbara Anaclerico, et al.
Hematological Oncology
|
May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
Francesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
Blood
|
March 7, 2009
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
Michele Baccarani, Gianantonio Rosti, Fausto Castagnetti, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
Blood
|
June 25, 2013
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
Simona Soverini, Caterina De Benedittis, K Machova Polakova, et al.
Blood
|
June 14, 2012
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
Simona Luatti, Fausto Castagnetti, Giulia Marzocchi, et al.
Blood Advances
|
February 27, 2026
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia
Harinder Gill, Francesca Palandri, David M Ross, et al.
Cancer Medicine
|
June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
Barbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
Blood Advances
|
June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib
Francesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.
Page
of 19
Search research articles
Search
Showing results (121-130 of 187) with videos related to
Sort By:
Page
of 19
Blood
|
April 1, 2011
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
Gabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, et al.
American Journal of Hematology
|
January 11, 2016
Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients
Alessandro Andriani, Roberto Latagliata, Barbara Anaclerico, et al.
Hematological Oncology
|
May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
Francesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
Blood
|
March 7, 2009
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
Michele Baccarani, Gianantonio Rosti, Fausto Castagnetti, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
Blood
|
June 25, 2013
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
Simona Soverini, Caterina De Benedittis, K Machova Polakova, et al.
Blood
|
June 14, 2012
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
Simona Luatti, Fausto Castagnetti, Giulia Marzocchi, et al.
Blood Advances
|
February 27, 2026
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia
Harinder Gill, Francesca Palandri, David M Ross, et al.
Cancer Medicine
|
June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
Barbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
Blood Advances
|
June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib
Francesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.
Page
of 19